Key signaling molecules in pituitary tumors

Related Experiment Video

Updated: Jun 18, 2026

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology
09:48

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology

Published on: February 25, 2022

Cristiana Pistol Tanase1, Monica Neagu, Radu Albulescu

  • 1Victor Babes National Institute of Pathology, 99-101 Splaiul Independentei, Sector 5, Bucharest, Romania. bioch@vbabes.ro

Expert Review of Molecular Diagnostics
|November 10, 2009
PubMed

Insights

Pituitary tumors involve complex signaling pathways. AKT and MAPK pathways are key targets for therapies like somatostatin analogues, while PTTG1 may serve as a malignancy biomarker.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Pituitary tumorigenesis involves intricate intracellular signaling pathways and microenvironmental factors.
  • Aberrant proliferation in pituitary tumors can result from alterations in key signaling molecules.
  • Overactivity in AKT and MAPK pathways is frequently observed.

Purpose of the Study:

  • To explore the role of intracellular signaling pathways in pituitary tumor development.
  • To identify potential therapeutic targets and biomarkers for pituitary tumors.
  • To investigate the clinical significance of PTTG1 in pituitary tumorigenesis.

Main Methods:

  • Analysis of intracellular signaling pathways, including AKT and MAPK.
  • Evaluation of the role of PTTG1 in pituitary tumor phenotypes and survival.
  • Review of existing evidence on therapeutic interventions and molecular mechanisms.

Main Results:

  • AKT and MAPK pathways are overactive and represent viable targets for somatostatin analogue inhibition.
  • PTTG1 shows significant correlation with aggressive tumor phenotypes and survival rates.
  • PTTG1 is a promising candidate biomarker for malignancy and tumor staging.

Conclusions:

  • Intracellular signaling molecules are crucial in pituitary tumor transformation.
  • Targeting AKT and MAPK pathways with somatostatin analogues offers therapeutic potential.
  • PTTG1 holds promise as a diagnostic, prognostic, and therapeutic target in pituitary oncology.

More Related Videos

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome12:34

Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome

Published on: April 2, 2018

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...